Ecor1 Capital, Llc Acquires 31,033 Shares of Zymeworks Inc. (NYSE:ZYME) Stock

Posted by Tech Dows on Mar 26th, 2025

Zymeworks Inc. (NYSE:ZYME – Get Free Report) Director Ecor1 Capital, Llc bought 31,033 shares of the company’s stock in a transaction on Friday, March 21st. The shares were bought at an average cost of $12.78 per share, for a total transaction of $396,601.74. Following the transaction, the director now directly owns 17,135,113 shares in the company, valued at approximately $218,986,744.14. This represents a 0.18 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Ecor1 Capital, Llc also recently made the following trade(s):

On Monday, March 24th, Ecor1 Capital, Llc acquired 22,689 shares of Zymeworks stock. The shares were bought at an average price of $13.08 per share, with a total value of $296,772.12.
On Wednesday, March 19th, Ecor1 Capital, Llc bought 58,306 shares of Zymeworks stock. The stock was purchased at an average price of $12.64 per share, with a total value of $736,987.84.
On Monday, March 17th, Ecor1 Capital, Llc purchased 56,277 shares of Zymeworks stock. The stock was purchased at an average price of $12.23 per share, for a total transaction of $688,267.71.
On Thursday, March 13th, Ecor1 Capital, Llc acquired 468,356 shares of Zymeworks stock. The shares were purchased at an average price of $12.48 per share, with a total value of $5,845,082.88.
On Tuesday, March 11th, Ecor1 Capital, Llc bought 320,690 shares of Zymeworks stock. The stock was purchased at an average price of $11.49 per share, with a total value of $3,684,728.10.
On Friday, January 17th, Ecor1 Capital, Llc purchased 19,748 shares of Zymeworks stock. The shares were acquired at an average cost of $13.87 per share, for a total transaction of $273,904.76.
On Wednesday, January 15th, Ecor1 Capital, Llc acquired 39,029 shares of Zymeworks stock. The stock was acquired at an average cost of $14.01 per share, with a total value of $546,796.29.
On Monday, January 13th, Ecor1 Capital, Llc bought 74,125 shares of Zymeworks stock. The shares were acquired at an average cost of $13.39 per share, for a total transaction of $992,533.75.
On Friday, January 10th, Ecor1 Capital, Llc purchased 204,098 shares of Zymeworks stock. The stock was acquired at an average cost of $13.13 per share, with a total value of $2,679,806.74.
On Wednesday, January 8th, Ecor1 Capital, Llc acquired 21,021 shares of Zymeworks stock. The stock was bought at an average cost of $14.07 per share, with a total value of $295,765.47.

Zymeworks Stock Performance

Shares of ZYME opened at $12.80 on Wednesday. The business’s 50-day moving average is $13.69 and its two-hundred day moving average is $13.73. The company has a market capitalization of $890.59 million, a P/E ratio of -8.53 and a beta of 1.13. Zymeworks Inc. has a fifty-two week low of $7.97 and a fifty-two week high of $17.70.

Institutional Trading of Zymeworks

Hedge funds have recently modified their holdings of the stock. Sterling Capital Management LLC lifted its holdings in Zymeworks by 781.5% in the fourth quarter. Sterling Capital Management LLC now owns 1,719 shares of the company’s stock valued at $25,000 after acquiring an additional 1,524 shares during the period. AlphaQuest LLC increased its holdings in shares of Zymeworks by 480.2% during the 4th quarter. AlphaQuest LLC now owns 2,808 shares of the company’s stock valued at $41,000 after purchasing an additional 2,324 shares in the last quarter. FMR LLC lifted its stake in shares of Zymeworks by 84.2% in the 3rd quarter. FMR LLC now owns 3,336 shares of the company’s stock valued at $42,000 after purchasing an additional 1,525 shares during the period. BNP Paribas Financial Markets purchased a new stake in Zymeworks during the fourth quarter worth $108,000. Finally, Tower Research Capital LLC TRC grew its position in Zymeworks by 343.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 9,704 shares of the company’s stock valued at $142,000 after buying an additional 7,518 shares during the period. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Citigroup boosted their target price on shares of Zymeworks from $18.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday, March 7th. Lifesci Capital started coverage on shares of Zymeworks in a report on Tuesday, March 11th. They set an “outperform” rating and a $30.00 price objective on the stock. HC Wainwright raised their target price on Zymeworks from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Monday, March 10th. JPMorgan Chase & Co. raised Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price target for the company in a research report on Monday, December 16th. Finally, Wells Fargo & Company increased their price objective on Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a report on Thursday, December 19th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Zymeworks has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

View Our Latest Stock Analysis on Zymeworks

About Zymeworks

(Get Free Report)

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.